Prep by diluting 5 mg phentolamine in 10 mL of 0.9% sodium chloride. Inject subcutaneously into the extravasation area within 12 hours of extravasation. Blanching should reverse immediately; additional to allow sufficient blood flow to the area of extravasation. ADULT Dose: 1000mg/m² (maximum 2000mg) on Days 1 and 2, 500mg/m² (maximum 1000mg) on day 3. Adjust dose for renal impairment. 

Mix each 500mg vial with 50mL of diluent (provided by manufacturer); mixed solution should be further diluted in 1000mL NS and begin administration within 4 hours. Infuse over 1 to 2 hours in a large caliber vein in an extremity/area other than the one affected by the extravasation. Cooling procedures such as ice packs should be removed from the area at least 15 minutes before administration in order to allow sufficient blood flow to the area of extravasation. ADULT Dose: 1000mg/m² (maximum 2000mg) on Days 1 and 2, 500mg/m² (maximum 1000mg) on day 3. Adjust dose for renal impairment.

The information provided is intended as a general guide only. Consult additional references and product labeling for more detailed information.


December 2009

Adapted from: St. Francis Hospital Department of Pharmacy Services Protocol

GUIDE TO EXTRAVASATION MANAGEMENT IN ADULT & PEDIATRIC PATIENTS

Related Policies
Nursing Standard of Practice & Procedures:
1) Extravasations, Patient Management of 2) Care of the Patient by a Non-Chemotherapy Certified RN

References

SPECIFIC SUBSTANCES

Calcium Carbonate
Etoposide
Teniposide
Vindesine
Vinorelbine
Dacarbazine
Potassium
Sodium bicarbonate
Ciplatin (> 20 ml and concentrations ≥ 0.5 mg/mL) Methotrexate
Dobutamine
Epinephrine
Norepinephrine
Phenylephrine
Aminophylline
Procainamide
Daunorubicin* Doxorubicin* Doxorubicin* Epirubicin* Arsenic trioxide
Bleomycin
Carboplatin
Cladribine
Cyclophosphamide
Cyrtarabine, Ipowalidol
Dacarbazine
Docetaxel
Doxorubicin*
Fluorouracil
Gemcitabine
Gemtuzumab
Idarubicin
Paclitaxel
Procarbazine
Streptozocin
Thiotepa
Topotecan
Valrubicin
Phentolamine
Sodium thiosulfate

PHYSICIAN'S ORDER

1. Patient cannot obtain follow-up care for any of the following: increased pain, skin color change, increased edema or swelling, or stiffness in the extremity, skin breakdown, fever, any additional questions. Provide instructions. Ensure that the patient is able to obtain follow-up care and evaluation. Describe the care of the site: elevate arm, use warm or cold compresses, protect from sun or abrasion; do not immerse in water. Instruct patient to call provider for any of the following: increased pain, skin color change, increased edema or swelling, stiffness in the extremity, skin breakdown, fever, any additional questions.


3. Instruct patient to call provider for any of the following: increased pain, skin color change, increased edema or swelling, or stiffness in the extremity, skin breakdown, fever, any additional questions. Provide instructions. Ensure that the patient is able to obtain follow-up care and evaluation. Describe the care of the site: elevate arm, use warm or cold compresses, protect from sun or abrasion; do not immerse in water. Instruct patient to call provider for any of the following: increased pain, skin color change, increased edema or swelling, stiffness in the extremity, skin breakdown, fever, any additional questions.

4. The information provided is intended as a general guide only. Consult additional references and product labeling for more detailed information.

5. Utilization of warm therapy may be more comfortable for patients with oxaliplatin-associated sensory neuropathy. The information provided is intended as a general guide only. Consult additional references and product labeling for more detailed information.

6. The information provided is intended as a general guide only. Consult additional references and product labeling for more detailed information.

7. The information provided is intended as a general guide only. Consult additional references and product labeling for more detailed information.

8. The information provided is intended as a general guide only. Consult additional references and product labeling for more detailed information.